🇺🇸 FDA
Patent

US 10981894

Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

granted A61PA61P5/00

Quick answer

US patent 10981894 (Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof) held by CRINETICS PHARMACEUTICALS, INC. expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRINETICS PHARMACEUTICALS, INC.
Grant date
Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P5/00